
1. j formos med assoc. 2018 jul;117(7):588-597. doi: 10.1016/j.jfma.2017.12.007.
epub 2018 feb 16.

phase iv randomized clinical study: peginterferon alfa-2a adefovir or
entecavir pre-therapy hbeag-positive chronic hepatitis b.

hsu cw(1), su ww(2), lee cm(3), peng cy(4), chuang wl(5), kao jh(6), chu hc(7),
huang yh(8), chien rn(9), liaw yf(10).

author information: 
(1)liver research unit, chang gung memorial hospital-linkou, chang gung
university college medicine, taoyuan, taiwan.
(2)changhua christian hospital, department internal medicine, changhua,
taiwan.
(3)chang gung memorial hospital-kaohsiung, chang gung university college of
medicine, kaohsiung, taiwan.
(4)china medical university hospital, department hepato-gastroenterology,
taichung, taiwan.
(5)kaohsiung medical university hospital, kaohsiung medical university,
kaohsiung, taiwan.
(6)national taiwan university hospital, department hepato-gastroenterology,
taipei, taiwan.
(7)tri-service general hospital, department internal medicine, taipei, taiwan.
(8)division gastroenterology hepatology, taipei veterans general hospital,
institute clinical medicine, national yang-ming university, taipei, taiwan.
(9)liver research unit, chang gung memorial hospital-linkou, chang gung
university college medicine, taoyuan, taiwan. electronic address:
ronald@adm.cgmh.org.tw.
(10)liver research unit, chang gung memorial hospital-linkou, chang gung
university college medicine, taoyuan, taiwan. electronic address:
liveryfl@gmail.com.

comment in
    j formos med assoc. 2018 aug;117(8):745-746.
    j formos med assoc. 2018 aug;117(8):747-748.

background: efficacy sequential therapy nucleos(t)ide analogues and
interferons versus monotherapy patients hepatitis b e antigen
(hbeag)-positive chronic hepatitis b (chb) remains unexplored. aimed assess
efficacy safety sequential therapy adefovir (adv) entecavir (etv) 
followed peginterferon (peg-ifn) alfa-2a taiwanese patients with
hbeag-positive.
methods: randomized, placebo-controlled, double-blind trial conducted at
nine sites taiwan april 2010 october 2013. patients (n = 280) were
randomized 1:1:1 receive placebo, etv adv alone four weeks, combined
with peg-ifn alfa-2a two weeks, peg-ifn alfa-2a alone 46 weeks. 
primary efficacy end point hbeag seroconversion 48 weeks post-treatment.
results: significant differences observed among groups hbeag
seroconversion (peg-ifn alfa-2a+placebo, 36.3%; peg-ifn alfa-2a+etv, 29.5%; and
peg-ifn alfa-2a+adv, 27.4%), hbeag loss (37.4%, 32.2%, 28.6%, respectively)
or change hepatitis b surface antigen (hbsag) levels baseline
(-0.56 iu/ml, -0.60 iu/ml, -0.41 iu/ml, respectively). however, hepatitis b
virus dna levels higher peg-ifn alfa-2a+placebo peg-ifn alfa+etv
at week 64 (p = 0.0412), 76 (p = 0.0311), 88 (p = 0.0113), alanine
aminotransferase (alt) normalization rate higher peg-ifn alfa-2a+placebo
than peg-ifn alfa-2a+adv (p = 0.0283) peg-ifn alfa-2a+etv (p = 0.0369) week
88. sub-analysis results revealed association on-treatment hbsag
and alt levels efficacy 48 weeks post-treatment. safety comparable among 
treatment groups.
conclusion: pre-therapy adv etv followed peg-ifn alfa-2a not
superior peg-ifn alfa-2a monotherapy taiwanese patients hbeag-positive
chb.
clinical trial id: nct: 00922207.

copyright © 2018. published elsevier b.v.

doi: 10.1016/j.jfma.2017.12.007 
pmid: 29456079  [indexed medline]

